Skip to main content

Complete tumour regression of in-transit melanoma following discontinuation of talimogene laherparepvec.

Journal articles  - Journal Article
Chen, AS; Proia, AD; Ho, L; Mosca, P
Published in: BMJ Case Rep
August 19, 2026

We report a case of complete tumour regression in a man in his 80s with in-transit melanoma following discontinuation of talimogene laherparepvec (T-VEC). The patient underwent a standard course of 1.0 mL of 1×10⁸ pfu/mL T-VEC every 2 weeks. After 10 T-VEC injections over approximately 5 months, the lesion still displayed fluorine-18 fluorodeoxyglucose activity on positron emission tomography/CT and biopsy-confirmed viable tumour. Due to side effects, including fatigue, headache and concern for a localised herpes simplex virus rash, the decision was made to discontinue T-VEC and perform surgical resection of the lesion. However, surgery was delayed by 8 weeks due to a minor stroke. After excision, the final pathology showed no residual melanoma, indicating a delayed, complete pathological response to T-VEC. This case may reflect the potential for continued or delayed anti-tumour immune activity after cessation of T-VEC and support further investigation into T-VEC's immune effects and timing of treatment in neoadjuvant settings.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

BMJ Case Rep

DOI

EISSN

1757-790X

Publication Date

August 19, 2026

Volume

19

Issue

8

Location

England

Related Subject Headings

  • Skin Neoplasms
  • Positron Emission Tomography Computed Tomography
  • Pathologic Complete Response
  • Melanoma
  • Male
  • Humans
  • Herpesvirus 1, Human
  • Biological Products
  • Antineoplastic Agents, Immunological
  • Aged, 80 and over
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Chen, A. S., Proia, A. D., Ho, L., & Mosca, P. (2026). Complete tumour regression of in-transit melanoma following discontinuation of talimogene laherparepvec. BMJ Case Rep, 19(8). https://doi.org/10.1136/bcr-2025-269006
Chen, Allan Samuel, Alan D. Proia, Lisa Ho, and Paul Mosca. “Complete tumour regression of in-transit melanoma following discontinuation of talimogene laherparepvec.” BMJ Case Rep 19, no. 8 (August 19, 2026). https://doi.org/10.1136/bcr-2025-269006.
Chen, Allan Samuel, et al. “Complete tumour regression of in-transit melanoma following discontinuation of talimogene laherparepvec.” BMJ Case Rep, vol. 19, no. 8, Aug. 2026. Pubmed, doi:10.1136/bcr-2025-269006.

Published In

BMJ Case Rep

DOI

EISSN

1757-790X

Publication Date

August 19, 2026

Volume

19

Issue

8

Location

England

Related Subject Headings

  • Skin Neoplasms
  • Positron Emission Tomography Computed Tomography
  • Pathologic Complete Response
  • Melanoma
  • Male
  • Humans
  • Herpesvirus 1, Human
  • Biological Products
  • Antineoplastic Agents, Immunological
  • Aged, 80 and over